SCHINDLER
Today, Schindler announced the formation of BuildingMinds, a start-up created to optimize the management of real estate assets through a software-as-a-service platform.
Partnering with Microsoft, BuildingMinds is using Microsoft’s Azure and Dynamics 365 cloud platforms. Building owners will benefit from the combination of Microsoft’s intelligent cloud and business applications and Schindler’s domain knowledge in servicing real estate customers globally.
BuildingMinds will offer a one-stop service platform for real estate asset optimization, transforming the way buildings are managed in the real estate sector. The start-up will develop a fully integrated, product-agnostic, cloud solution that improves transparency and operational efficiency by allowing building owners to centrally manage all their properties and service providers.
Founded in Berlin, Europe’s prominent hub for property technology start-ups, BuildingMinds will serve customers worldwide and plans to grow its team to over 100 digital experts by year-end.
“Our partnership combines Schindler’s world-class expertise in the building management industry with the power of Microsoft technology to drive innovation across the sector. BuildingMinds will offer a range of smart building solutions, tailored to help building owners around the world facing daily operational challenges,” said Jean-Philippe Courtois, Executive Vice President and President, Microsoft Global Sales, Marketing and Operations.
“Today, properties use different supplier applications often unconnected with one another. As digitization advances, real estate owners face the challenge of managing the data locked in such an array of diverse applications within their portfolio of buildings,” said Jens Mueller, Chief Operating Officer of BuildingMinds.
“The demand for data-driven intelligence in building management and real estate asset optimization is significant and growing. Combining our industry insights with our digitization expertise will enable BuildingMinds to play a role in leading the change taking place in the sector,” said Silvio Napoli, Chairman of the Schindler Group. “This will close a long-standing gap in the advent of smart buildings, and we are pleased to be partnering with a global leader such as Microsoft on this pivotal initiative.”
Market research firm Orbis Research forecasts that the global smart-building market is expected to grow from around USD 8 billion in 2016 to around USD 58 billion by 2023. To tap into the opportunities of digitization, real estate companies are investing in new solutions that integrate their properties with their suppliers’ ecosystems and broader asset portfolio. By joining forces, BuildingMinds and Microsoft are bringing together the capabilities needed to accelerate this transformation.
BuildingMinds will operate as a stand-alone company within the Schindler Group. As its sole shareholder, Schindler has allocated funding of up to EUR 150 million to the start-up, a quarter of which it expects to expense in 2019.
About BuildingMinds
BuildingMinds enables the transformation of real estate into smart buildings, connecting real estate assets across the whole value chain through its fully integrated one-stop cloud platform. www.buildingminds.com
About Microsoft
Microsoft enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more. www.microsoft.com
About Schindler
Founded in Switzerland in 1874, the Schindler Group is a leading global provider of elevators, escalators, and related services. Schindler mobility solutions move more than one billion people every day all over the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005705/en/
Contact:
For further information: Nelly Keune, Chief Communications Officer Tel. +41 41 445 30 60, nelly.keune@schindler.com Marco Knuchel, Head of Investor Relations Tel. +41 41 445 30 61, marco.knuchel@schindler.com
Zugerstrasse 13 6030 Ebikon Switzerland
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom